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Therapy of selected human malignancies with interferon-a is widely accepted but often complicated by the emergence of
interferon-a resistance. Interferon is a pleiotropic cytokine with antiproliferative, antitumour, antiviral and immunmodulatory
effect; it signals through the Jak-STAT signal transduction pathway where signal transducer and activator of transcription 1 plays
an important role. Here we report both, a lack of signal transducer and activator of transcription induction in interferon-a
resistant renal cell carcinoma cells and signal transducer and activator of transcription 1 reinduction of phorbol 12-myristate
13-acetate-stimulated peripheral blood mononuclear cells supernatant. Preliminary experiments on the identiﬁcation of the
molecules that reinducing signal transducers and activators of transcription 1 indicate that interferon-g may be the responsible
candidate cytokine, but several others may be involved as well. This work provides the basis for therapeutic strategies directed
at the molecular modulation of interferon-a resistance in human neoplasms.
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Interferon-a (IFN-a) plays an important role in the treatment of
various human malignancies, among them renal cell carcinoma
(Dorr, 1993); however, response to IFN-a is often impaired by
the development of IFN-resistance (Devita et al, 1989), mechan-
isms of which are poorly understood.
Interferon-a belongs to a group of cytokines with antiviral, anti-
proliferative, antitumour and immunmodulatory activities (Pestka
et al, 1987). Binding of IFN-a to the IFN Type I receptor results
in oligomerization of the receptor subunits and subsequent trans-
phosphorylation of receptor-associated Janus-kinases Jak1 and
Tyk2; activated Jak1 and Tyk2 subsequently phosphorylate tyrosine
residues on the associated receptor chain. Signal transducers and
activators of transcription (STAT) 1 and 2 can then bind to the
receptor by their SH2 domains which are thereupon tyrosine phos-
phorylated by the receptor-associated Janus-kinases; thereafter, the
STATs are released from the receptor and form STAT1-STAT2-
heterodimers which translocate to the nucleus where they bind
with p48 to form the interferon stimulated gene factor 3 (ISGF3).
ISGF3 binds to the interferon stimulated response element (ISRE)
in the promoter of IFN-induced genes resulting in transcription of
interferon-stimulated genes (ISG) (Schindler and Darnell, 1995;
Haque and Williams, 1998).
There is evidence that IFN-a resistance is associated with defec-
tive components of the Jak-STAT-Pathway (Pansky et al, 2000)
e.g., defective activation of ISGF3 (Xu et al, 1994; Wong et al,
1997), lack of STAT1 expression (Sun et al, 1998) or STAT3 induc-
tion (Yang et al, 1998). It has been reported that sequential
treatment of interferon resistant cells with retinoic acid or tamox-
ifen followed by interferon-a up-regulates STAT1 expression and
ISGF3 activation, respectively, in cells which do not respond to
either single agent (Kolla et al, 1996; Lindner et al, 1997).
Here we sought (a) to characterize STAT1 deﬁciency associated
with IFN-a resistance and (b) to identify modulators of STAT1
induction. These studies provide the basis for a potential modula-
tion of resistance to IFN-a in renal cell carcinoma ex-vivo as well as
in renal cell carcinoma patients receiving systemic IFN-a.
MATERIALS AND METHODS
Cells and culture conditions
A-498 and Caki-2 cells were obtained from ATCC (Rockville, USA)
(Cat. No. HTB 44). The fresh RCC cells were established according
to Ebert et al (1990). Cells were grown in RPMI 1640 supplemen-
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www.bjcancer.comted with 10% heat-inactivated FCS, 2 mML -glutamine,
50 mg ml
71 streptomycin and 50 IU ml
71 penicillin at 378Ci n
an atmosphere containing 5% CO2 and passaged once a week.
Reagents
Interferon-a-2a (Roferon A
1 (18610
6 IU), Hoffmann-LaRoche,
Basel, Switzerland) was dissolved in Aqua bidest, diluted with
RPMI 1640 and stored in aliquots of 1610
6 IU at 48C. IFN-a
was used in a ﬁnal concentration of 1000 IU ml
71. IFN-g-1b
(Imukin
1 (3610
6 IU)) was obtained from Boehringer Ingelheim,
dissolved in Aqua bidest and stored in aliquots of 10 ng ml
71
(300 IU ml
71)a t4 8C. Phorbol 12-myristate 13-acetate (PMA)
was obtained from Sigma. It was dissolved in DMS and stored as
aliquots (10 mgm l
71)a t4 8C.
Interferon-a-2a dose titration
Cells were tested for IFN-a resistance using different IFN-a-2a
concentrations (10, 100, 1000, 10000 IU ml
71) in the Cell Prolif-
eration ELISA, BrdU (colorimetric), (Roche Molecular
Biochemicals, Mannheim, Germany).
A relative resistance to the antiproliferative effects of interferon-
a was best produced by continuous incubation of the A-498 and
fresh renal cell carcinoma (RCC) cells with 1000 IU ml
71 interfer-
on-a over 3–4 months.
Preparation of PMA-stimulated PBMC supernatant
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy-coat leucocyte concentrates of healthy donors by Ficoll gradient
centrifugation. The cells were cultured in RPMI 1640 supplemented
as indicated above and stimulated with 10 ng ml
71 PMA for 4 days.
After centrifugation for 10 min at 225 g the media was decanted and
again centrifuged for 10 min at 2000 g. The supernatant was diluted
1:2 with RPMI 1640 and added to the cells.
Whole cell extracts
Cells were treated with IFN-a, IFN-g and supernatant as single agents,
as well as with combinations of IFN-a and supernatant for various
times as indicated in Figures 1–5, 7. IFN-a or IFN-g was added
during the last 30 min of incubation with supernatant. Cells were
washed with ice-cold phosphate-buffered saline (PBS) and resus-
pended in RSB buffer (10 mM Tris (pH 7.4); 10 mM NaCl; 1.5 mM
MgCl2;1 0 m M NaF; supplemented with 0.15 mM PMSF; 1 mM
DTT; 0.2 mM Na3VO4) and incubated 10 min on ice for swelling.
After centrifugation at 15800 g for 10 s at 48C, cells were resus-
pended in buffer C (20 mM HEPES; 420 mM NaCl; 1.5 mM MgCl2;
0.2 mM EDTA; 25% Glycerin; 10 mM NaF; supplemented with
0.15 mM PMSF; 1 mM DTT; 0.2 mM Na3VO4), sucked up and down
5–10 times in a 26 G syringe and incubated on ice for 45 min. Whole
cell extract was obtained by centrifugation at 15800 g for 10 min at
48C. The supernatant (=whole cell extract) was shock frozen in liquid
nitrogen at 71758C and stored at 7808C until use.
Electrophoretic mobility shift assay (EMSA)
As STAT1 binding site we used the b-Casein (5'-TCGAAGATTTC-
TAGGAATTCAATC-3')o rF c gRI-GAS (5'-TCGATTTGAGATGTA-
TTTCCCAGAA-3'). The oligos were synthesized at Roth, Karls-
ruhe, Germany and labelled at the 5'-end with
32P. Brieﬂy whole
cell extracts of equal protein concentration were incubated with
the labelled oligo in 200 mM KCl; 2 mM MgCl2; 0.5 mM EGTA;
2.5 mM DTT; 100 mM HEPES (pH 7.9); 50% Glycerine and
Poly-d(I-C) for 30 min at room temperature. For competition
assays 1 ml monoclonal STAT1-antibody (Santa Cruz Biotechnol-
ogy, Inc.) or 50-, 100- and 300-fold excess of unlabelled oligo
were used. Electrophoresis was performed on a 6% non-denaturat-
ing polyacrylamide gel at 300 V for 15 min and 380 V for 2 h in
the cold. Gels were dried and exposed to X-Omat AR 5 ﬁlms
(Kodack, Stuttgart, Germany) for 1 to 3 days.
STAT1-reinduction experiments of g-interferon
Based on experiments of Venkataraman et al (1999) IFN-g-1b was
used in a concentration of 10 ng ml
71. Experiments were
performed in duplicate.
Statistical analysis
Assays were regularly performed in triplicates and statistical means
were established.
RESULTS
IFN-a associated antiproliferative effect and STAT1
induction in RCC cells
The RCC cell lines A-498 and Caki-2 and fresh RCC cells were
assessed for the antiproliferative effect of IFN-a by a cell prolifera-
tion ELISA based on BrdU incorporation. In A-498 and fresh RCC
cells, IFN-a inhibited cell proliferation in a dose-dependent manner
while in Caki-2 cells, IFN-a showed no antiproliferative effect (data
not shown).
As IFN-a is known to induce STAT1 in various cell types, cells
were investigated for STAT1 induction. Cells were incubated for
30 min with 1000 IU ml
71 interferon-a and assessed for STAT1
induction by EMSA. We found that in A-498 and fresh RCC cells
IFN-a induced STAT1 but not in Caki-2 cells, suggesting that
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Figure 1 Electrophoretic mobility shift assays for IFN-a induced STAT1
induction. IFN-a sensitive (S) and IFN-a resistant (R) A-498 and fresh
RCC cells and Caki-2 cells were either left untreated or incubated with
1000 IU ml
71 IFN-a for 30 min. Lanes 1–5 are A-498 cells: lanes 1 and
4, untreated IFN-a sensitive and resistant cells, respectively; lanes 2, 3 and
5, IFN-a stimulated IFN-a sensitive and resistant cells, respectively. Lanes
6 and 7 are Caki-2 cells: lane 6, untreated Caki-2 cells; lane 7, IFN-a stimu-
lated cells. Lanes 8–11 are fresh RCC cells: lanes 8 and 10, untreated IFN-a
sensitive and resistant cells, respectively; lanes 9 and 11, IFN-a stimulated
IFN-a sensitive and resistant cells, respectively. STAT1 induction can be de-
tected in sensitive A-498 and fresh RCC cells after stimulation with IFN-a
but not in resistant cells (lanes 2 and 9). STAT1 can be competed with
monoclonal anti-STAT1 antibody (lane 3) (see arrow for STAT1 band).
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associated with defective STAT1 induction (Figure 1).
Identity of STAT1 was conﬁrmed by adding STAT1-mAb which
selectively blocked the STAT1-band.
IFN-a resistant A-498 and RCC cells are defective in the
induction of STAT1
IFN-a resistance of A-498 and fresh RCC cells, respectively, was
induced by culturing the cells over 3–4 months in 1000 IU ml
71
IFN-a. A relative resistance to IFN-a in A-498 and fresh RCC cells
was subsequently conﬁrmed by cell proliferation ELISA.
An EMSA for determination of STAT1 activity was performed as
indicated above. IFN-a failed to induce STAT1 induction in resis-
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Figure 2 Electrophoretic mobility shift assays for STAT1 induction in A-
498 cells by PMA-stimulated PBMC supernatant. (A) Electrophoretic mo-
bility shift assay for STAT1 induction in IFN-a sensitive (S) A-498 cells by
PMA-stimulated PBMC supernatant. Cells were either left untreated (lane
1) or treated with IFN-a alone (lane 2) or supernatant alone (lanes 3, 5, 7,
9) or with their combination (lanes 4, 6, 8 and 10). STAT1 is induced in the
presence of IFN-a (lanes 2, 4, 6, 8 and 10) and after incubation for 1 h with
the supernatant (lane 3) (see arrow for STAT1 band). (B) STAT1 induction
in IFN-a resistant (R) A-498 cells by PMA-stimulated PBMC supernatant.
Cells were treated with IFN-a alone (lane 3) or supernatant alone (lanes
4, 6, 8 and 10) or with their combination (lanes 5, 7, 9 and 11). IFN-a does
not induce STAT1 (lane 3) but treatment with supernatant alone and in
combination with IFN-a for 1, 4 and 6 h can induce STAT1 induction (lanes
4–9). IFN-a treated A-498 S cells served as positive control (lane 1) (see
arrow for STAT1 band).
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Figure 3 Electrophoretic mobility shift assays for STAT1 induction in
fresh RCC tumour cell culture by PMA-induced PBMC supernatant. (A)
STAT1 induction in IFN-a sensitive (S) fresh RCC tumour cell culture by
PMA-induced PBMC supernatant. Cells were either left untreated (lane
2) or treated with IFN-a alone (lane 3) or supernatant alone (lanes 4, 6,
8 and 10) or with their combination (lanes 5, 7, 9 and 11). STAT1 is in-
duced in the presence of IFN-a (lane 3, 5, 7, 9 and 11) and after incubation
for 1 h with the supernatant (lane 4). IFN-a treated A-498 S cells served as
positive control (lane 1) (see arrow for STAT1 band). (B) STAT1 induction
in IFN-a resistant (R) fresh RCC cells by PMA-stimulated PBMC superna-
tant. Cells were either left untreated (lane 1) or were treated with IFN-a
alone (lane 2) or supernatant alone (lanes 3, 5, 7 and 9) or with their com-
bination (lanes 4, 6, 8 and 10). IFN-a did not induce STAT1 (lane 2) but
treatment with supernatant alone and in combination with IFN-a for 1 h
induced STAT1 induction (lanes 3 and 4). IFN-a treated A-498 S cells
served as positive control (lane 11) (see arrow for STAT1 band).
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and fresh RCC cells, respectively (Figure 1).
PMA-stimulated PBMC supernatant can reinduce STAT1
in IFN-a resistant A-498 and fresh RCC cells
The supernatant was prepared as described below. A-498 cells were
treated for 1, 4, 6 and 24 h either with the supernatant alone or
with supernatant followed by 30 min 1000 IU ml
71 interferon-a
as indicated in Figure 2A,B.
In the sensitive cells, the supernatant alone induced a visible
band after 1 h of incubation, only. In the presence of IFN-a,a
STAT1-band was detectable at all time points (Figure 2A). The
supernatant alone and its combination with IFN-a were able to
restore STAT1 induction in resistant cells. The most intense
STAT1-band was detected after 1 h of stimulation, it was signiﬁ-
cantly less intense 4 and 6 h and disappeared at 24 h (Figure
2B). When repeated with the PBMC supernatant of another donor,
this assay led to the identical results (data not shown).
As we sought to exclude a cell line speciﬁc effect of the superna-
tant, we treated fresh RCC cells in the same manner. These cells were
ﬁrst derived from one RCC patient, and an IFN-a resistant variant
which also lacks STAT1 induction was subsequently generated.
In sensitive cells, the supernatant alone induced a weak STAT1-
band after only 1 h. As expected in the presence of interferon-a,
STAT1 was induced at all time points (Figure 3A). The present
supernatant reinduced STAT1 in the IFN-a resistant cells with a
clearly detectable band after 1 h (Figure 3B); Interferon-a treated
A-498 S cells served as positive control for STAT1.
In Caki-2 cells, PMA-stimulated PBMC supernatant cannot
reinduce STAT1
As the supernatant induced optimal STAT1 in A-498 and fresh
RCC cells after 1 h, Caki-2 cells were treated for 1 h with superna-
tant alone or in combination with IFN-a. Neither the supernatant
alone nor its combination with interferon reinduced STAT1 in
Caki-2 cells (Figure 4).
Conﬁrmation of supernatant-induced STAT1 via
competition with STAT1-mAb and unlabelled oligo
To conﬁrm that the band induced by the present supernatant
correlated to STAT1, a competitional assay was performed with
STAT1-mAb and with 50-, 100- and 300-fold excess of unlabelled
oligo, which all blocked the STAT1-band (Figure 5).
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Figure 5 Conﬁrmation of supernatant-induced STAT1 via competition with STAT1-mAb and unlabelled oligo. Supernatant-induced STAT1 induction in
IFN-a sensitive (S) A-498 cells (lane 2) and IFN-a resistant (R) A-498 cells (lanes 7 and 12) can be competed with STAT1-mAb (lanes 6, 11 and 16) or 50-,
100- and 300-fold excess of unlabelled oligo (lanes 3–5, 8–11, 13–15) (see arrow for STAT1 band).
12 3 4
Figure 4 Electrophoretic mobility shift assay for STAT1 induction in
Caki-2 cells by PMA-induced PBMC supernatant. Lanes 2–4 are Caki-2
cells: Lane 2 are untreated Caki-2 cells. Cells were treated with supernatant
alone (lane 3) or with IFN-a and supernatant (lane 4). There is no STAT1
induction detectable in Caki-2 cells. IFN-a treated A-498 S cells served as
positive control (lane 1) (see arrow for STAT1 band).
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induce STAT1
In order to demonstrate that the effect of STAT1 reinduction was
due to the cytokines secreted by PMA-stimulated PBMC and not
by PMA itself, A-498 cells were incubated with 10 ng ml
71 of
PMA either alone and in combination with IFN-a. PMA alone
did not induce STAT1 neither in the sensitive nor in the resistant
cells, while the combination of PMA and IFN-a induced STAT1 in
the sensitive cells, but not in the resistant cells (Figure 6A,B).
IFN-g alone does induce STAT1
To investigate the cytokine potentially capable of STAT1 reinduc-
tion, IFN-a resistant A-498 cells were incubated with IFN-g 1b
(10 ng ml
71), which clearly reinduced STAT1. A-498 sensitive
and resistant cells treated with IFN-a were used as positive and
negative control for STAT1 (Figure 7).
DISCUSSION
Response to IFN-a is often impaired by the development of IFN-
resistance (Devita et al, 1989). Many mechanisms have been
proposed to mediate IFN-a resistance in various different cell
types: lack of ISGF3 (Xu et al, 1994; Wong et al, 1997) or one
of its components (Dron and Tovey, 1993; Sun et al, 1998),
decrease in ISG expression (Affabris et al, 1983; Salzberg et al,
1983), lack of a high afﬁnity receptor site (Hannigan et al, 1984)
or the development of anti-interferon antibodies in patients (Ques-
ada et al, 1985; Steis et al, 1988). However, there seems to be no
unique mechanism for all cells given reports on interferon-resistant
cells which do not inherit one of the above defects (Grups and
Bange, 1990; Talpaz et al, 1992). While an interferon-resistant cell
line with entire STAT1 induction has been reported (Yang et al,
1998), STAT1 seems to be an essential component of interferon
signalling as STAT1 deﬁcient mice do not respond to interferons
and are highly sensitive toward viral infections (Durbin et al,
1996; Meraz et al, 1996); in addition complementation of the
IFN-unresponsive mutant cell line U3 interferon with STAT1,
cDNA constructs reportedly restores ISGF3 formation and tran-
scriptional response to interferon (Mu ¨ller et al, 1993).
Here, we detected a deﬁcient STAT1 induction in two different
RCC sublines, with secondary interferon-a resistance and in a
primary resistant RCC cell line. There were several possibilities to
explain the defect, e.g.: (a) decreased synthesis, increased degrada-
tion, decreased tyrosine phosphorylation of STAT1; (b)
malfunction in the preceding steps of the signal transduction path-
way; or (c) lack of STAT1 transcript due to a mutation in the
STAT1 gene.
In the present experiments, the PMA-stimulated PBMC superna-
tant reinduced STAT1 in A-498 and fresh RCC cells with secondary
IFN-a resistance but not in primary resistant Caki-2 cells. This
indicated that in resistant A-498 and fresh RCC cells, the STAT1
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Figure 6 Electrophoretic mobility shift assays for STAT1 induction by
10 ng ml
71 PMA. (A) STAT1 induction in IFN-a sensitive (S) A-498 cells
by 10 ng ml
71 PMA. Cells were either left untreated (lane 1) or were trea-
ted with IFN-a alone (lane 2) or PMA alone (lanes 3, 5, 7 and 9) or with
their combination (lanes 4, 6, 8 and 10). STAT1 indiction can be detected
after incubation with IFN-a alone (lane 2) and in combination with PMA
(lanes 4, 6, 8 and 10). PMA alone does not induce STAT1 (lanes 3, 5, 7,
9) (see arrow for STAT1 band). (B) STAT1 induction in IFN-a resistant
(R) A-498 cells by 10 ng ml
71 PMA. Cells were either left untreated (lane
2) or were treated with IFN-a alone (lane 3) or PMA alone (lanes 4, 6, 8
and 10) or with their combination (lanes 5, 7, 9 and 11). IFN-a and PMA
alone as well as their combination fail to induce STAT1 in resistant cells.
IFN-a treated A-498 S cells were used as positive control (lane 1) (see ar-
row for STAT1 band).
1234 56
Figure 7 Sensitive (S) cells were either left untreated (lane 1) or were
treated with IFN-a alone (lane 2) or with the combination of IFN-a and
a monoclonal STAT1 antibody (lane 3). Resistant (R) cells were either left
untreated (lane 4) or were treated with IFN-a alone (lane 5) or with IFN-g
alone (lane 6). IFN-a fail to induce STAT1 in resistant cells (but it was pos-
sible to induce STAT1 in the sensitive cells). The signal extinguished in sen-
sitive cells when a commercially available monoclonal STAT1 antibody was
added (lane 3). In contrast IFN-g was able to reinduce STAT1 in IFN-a re-
sistant cells (lane 6). Untreated A-498 S and R cells were used as negative
controls (lanes 1 and 4).
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in the signal transduction pathway appears to be more extensive.
Previously, Sun et al (1998) reported a lack of STAT1 transcript
in IFN resistant lymphoma cells. Here a mutation in or a loss of
the STAT1 gene could explain why Caki-2 cells were refractory
to PMA-PBMC-mediated STAT-reinduction.
It is known that PMA-stimulated PBMC produce a number of
cytokines; as observed there are several cytokines including IL-2,
IL-6, IL-9, IL-10, IL-11, IFN-g, hormones as growth hormone
and prolactin and growth factors as GCSF, EGF, PDGF, CSF-1
and angiotensin which may induce STAT1 in various cell types
(Schindler and Darnell, 1995; Briscoe et al, 1996; Ihle, 1996;
Leaman et al, 1996).
Here, we demonstrated that IFN-g reinduces STAT1 in IFN-a
resistant A-498 cells; this suggested that IFN-g may be the PMA-
stimulated PBMC derived cytokine capable of reinducing STAT1
but several others may be involved as well. Since biological effects
of IFN-a and IFN-g are both mediated by Jak1, it appeared that
Tyk2 tyrosine kinase or the receptor may be impaired in IFN-a
resistant carcinoma cells upstream of STAT1.
The signiﬁcance of the additional STAT1 inducers remained
unclear as their biological effects are not necessarily mediated by
a Jak-STAT signal transduction pathway or require STAT1 induc-
tion. Previously, STAT1 deﬁcient mice responded normally to
growth hormone, EGF and IL-10 which induce STAT1 in vitro
(Meraz et al, 1996). STAT1 induction by cytokines other than
interferons were cell-speciﬁc (Schindler and Darnell, 1995; Han et
al, 1996). Therefore, in RCC some of these known cytokines may
actually not be able to induce STAT1, while there might be addi-
tional inducers.
Future experiments will focus on further steps toward the iden-
tiﬁcation of those molecular regulators associated with IFN-a
resistance in order to provide new modalities of treatment for renal
cell carcinoma patients.
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